NBSE
NeuBase Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.
Market Cap: 3.36 Million
Primary Exchange: NASDAQ
Website: https://www.neubasetherapeutics.com/
Shares Outstanding: 3.73 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6978102579592793
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 984 trading days
From: 2021-02-09 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|